Skip to content
We know skin / Entendemos la pielEspañol
Skinpaths

Disease directory

Dermatofibroma

Published: September 18, 2026Updated: September 18, 2026

Important: Informational content intended for healthcare professionals. It does not replace clinical evaluation or establish a doctor-patient relationship.

Overview

  • Names: Dermatofibroma, Benign cutaneous fibrous histiocytoma, Dermal histiocytoma / cutaneous fibrohistiocytoma Myers 2025 , Wan 2025 .
  • History
    • The entity described as a benign cutaneous fibrous histiocytoma since the first half of the 20th century; the name “dermatofibroma” was consolidated in the literature of cutaneous pathology in the second half of the 20th century, reviewed in depth by Zelger et al. Zelger 2004 .
    • Variants (atrophy, aneurysmal, lipidized, epithelioid, cellular, etc.) have been described over the last few decades Zelger 1995 , Iwata 2000 , Alves 2014 .
  • Epidemiology
    • Very common benign skin tumor.
    • More common between 20–50 years of age, with a clear female predominance (approx. 2–4:1) Myers 2025 , He 2025 .
    • Typical location: lower (legs) and upper extremities; trunk to a lesser extent Myers 2025 , Estela 2014 .
    • The lesion is usually solitary. Multiple or eruptive forms are rare and may be associated with immunosuppression or HIV (Wan 2025 ).
    • In pediatrics: less frequent; only ~5% of cases in <5 years in large series Berklite 2020 .
  • Codes
    • ICD-10-CM : coded as D23.x – Other benign skin tumors , choosing the subcode according to location (face D23.3, scalp/neck D23.4, trunk D23.5, upper limbs D23.6, lower limbs D23.7, unspecified skin D23.9).
    • ICD-11 : 2F23.0 – Dermatofibroma , within “Benign cutaneous neoplasms”
  • Diagnostic checklist (quick)
    • Essential clinic
      • Firm nodule/papule 2–10 mm, usually on extremities, reddish-brown or skin-colored.
      • Positive dimple sign.
      • History of slow growth and stabilization; no systemic symptoms.
    • Dermatoscopy (typical case)
        • Peripheral pigmented network ± delicate vessels.
        • Whitish/scarred central area or pattern compatible with any of the described variants.
    • Mandatory supplementary examinations only if:
        • Large, deep, recurrent or markedly atypical lesion → consider imaging (ultrasound/MRI) and/or molecular study to rule out DFSP or sarcoma.
        • Multiple/eruptive lesions → screening for SLE, HIV, other connective tissue diseases or hematological malignancies.

Doctors who treat Dermatofibroma

Directory specialists related to Dermatofibroma.

There are no specialists associated with this record yet

You can browse the full directory and filter by the condition you're interested in.

Go to directory